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Background  :  The  prevalence  and  clinical  significance  of  white-coat  hypertension  (WCHT)  and  masked 
hypertension  (MHT)  are  unknown  in  Koreans.  Here  we  measure  the  frequency  of  WCHT  and  MHT  in  hypertensive 
subjects  and  identify  the  epidemiologic  and/or  clinical  factors  that  predict  it  in  Korean  subjects. 
Methods  :  This  study  is  a  retrospective  analysis  of  a  random  sample  from  February  2004  to  October  2005.  All 
patients  had  measurements  of  blood  pressure  (BP)  in  the  clinic  and  24-hour  ambulatory  blood  pressure  monitoring 
(ABPM).  Subjects  were  classified  into  four  groups  on  the  basis  of  daytime  ambulatory  BP  and  clinic  BP  level:  1) 
Normotension  (NT),  2)  MHT,  3)  WCHT,  and  4)  sustained  hypertension  (SHT). 
Results  :  For  all  967  patients,  the  mean  clinic  BP  was  157.7±22.0/  95.3±13.1  mmHg,  and  the  mean  daytime 
ambulatory  BP  was  136.4±15.0/  86.2±10.7  mmHg.  The  NT,  MHT,  WCHT,  and  SHT  groups  consisted  of  51  (5.3%), 
55  (5.7%),  273  (28.2%),  and  588  (60.8%)  subjects,  respectively.  The  left  ventricular  mass  index  was  significantly  higher 
in  SHT  than  in  the  other  groups,  and  was  positively  correlated  with  BP,  especially  ABPM.  Compared  with  NT,  the 
factors  associated  with  MHT  were  younger  age,  male  gender,  higher  BMI,  clinic  BP  ≥130  mmHg,  and  alcohol 
consumption.  Compared  with  SHT,  the  factors  associated  with  WCHT  were  female  gender,  lower  BMI,  and  clinic  BP 
<  150  mmHg. 
Conclusions  :  WCHT  and  MHT  were  prevalent  in  the  hypertensive  population.  ABPM  was  more  predictive  of  target 
organ  damage  than  clinic  BP,  and  could  be  useful  in  identifying  subjects  at  risk  for  WCHT  and  MHT.
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INTRODUCTION
Hypertension  is  a  risk  factor  for  diseases  of  the  cardiova-
scular  system.  Mean  daytime  ambulatory  blood  pressure  (BP) 
better  reflects  cardiovascular  risk  than  mean  clinic  BP  measured 
in  a  medical  office,  especially  since  daily  fluctuations  in  BP 
reflect  the  actual  BP  to  which  individuals  are  exposed.  Ambula-
tory  blood  pressure  monitoring  (ABPM)  over  24  hours  is 
therefore  an  important  means  of  diagnosing  and  managing 
hypertension
1-3).  With  the  introduction  of  24-hour  ABPM, 
conventional  hypertension  has  been  subclassified  as  white-coat 
hypertension  (WCHT),  in  which  patients  exhibit  elevated  clinic 
BP  but  normal  daytime  ambulatory  BP;  masked  hypertension 
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but  normal  clinic  BP;  and  sustained  hypertension  (SHT),  in 
which  patients  exhibit  elevated  clinic  and  daytime  ambulatory 
BP
4, 5). 
WCHT  is  present  in  about  7%  to  12%  of  the  general  popula-
tion,  and  in  12%  to  50%  among  stage  1  and  2  hypertension 
groups  by  the  JNC-6  guidelines
6-8).  Factors  predictive  of  WCHT 
include  female  gender,  low  educational  level,  low  clinic  BP, 
smoking  history,  and  low  BMI
6, 7, 9, 10).  The  degree  of  target 
organ  damage
11-15)  and  long-term  cardiovascular  risk
11, 16-18)  in 
WCHT  patients  is  higher  than  normotensive  (NT)  subjects,  but 
less  than  in  subjects  with  SHT. 
MHT  is  present  in  about  10%  of  patients  with  hypertension
2, 7, 8, 19). 
Factors  predictive  of  MHT  include  younger  age,  male  gender,  high 
BMI,  high  clinic  BP,  and  a  history  of  habitual  drinking
7, 20).  Target 
organ  damage  and  cardiovascular  risk  in  subjects  with  MHT  a
re  similar  or  slightly  lower  than  those  of  SHT
8, 19, 21). 
While  measurement  of  ambulatory  BP  for  24  hours  is 
essential  to  the  diagnosis  of  WCHT  or  MHT,  these  conditions 
are  not  easy  to  diagnose  in  Korea,  because  measurements  of 
daytime  ambulatory  BP  are  not  yet  common.  Accordingly,  we 
assessed  the  prevalence  of  WCHT  and  MHT  in  hypertensive 
patients  who  were  followed-up  with  an  ABPM  device.  We  also 
determined  the  dynamic,  demographic,  and  clinical  factors 
predictive  of  WCHT  and  MHT,  as  well  as  their  effects  on  target 
organ  damage,  in  Korean  subjects. 
MATERIALS AND METHODS
Subjects
The  subjects  of  this  study  were  hypertensive  patients  ≥15 
years  old  at  an  early  stage  of  diagnosis  who  visited  the 
outpatient  unit  of  the  Department  of  Cardiology  at  Asan  Medical 
Center  between  February  2004  and  October  2005,  and  who  had 
undergone  24  hours  of  ABPM.  Subjects  with  serious  cardiova-
scular  complications,  such  as  coronary  artery  disease  and 
stroke,  at  their  first  visit  were  excluded. 
Methods
Demographic  characteristics  recorded  at  the  first  visit 
included  age,  sex,  height,  weight,  medication,  smoking  history, 
drinking  history,  combined  diseases,  and  a  family  history  of 
hypertension.  Blood  was  drawn  for  measurement  of  total  serum 
cholesterol,  triglycerides,  HDL  and  LDL  cholesterol,  blood  sugar, 
creatinine,  and  uric  acid.  Echocardiographic  exams  were  done, 
depending  on  the  doctor's  decision,  to  obtain  the  left  ventricular 
mass  index  (LVMI)  and  aortoseptal  angle  (AoSA).  LVMI  was 
calculated  by  dividing  the  left  ventricular  muscles  by  surface 
area
22),  and  AoSA  was  measured  from  the  parasternal  long-axis 
view  immediately  before  the  opening  of  the  aortic  valve,  with 
AoSA  increases  defined  as  over  120
23). 
Clinic  BP  and  24-hour  ABPM  were  measured  using  standard 
procedures.  If  subjects  were  taking  antihypertensive  medications, 
they  were  stopped  for  3  to  7  days  prior  to  measurements  of 
clinic  BP  and  24-hour  ABPM.  Based  on  mean  daytime  blood 
pressure  (6  am  to  10  pm)  of  clinic  BP  and  24-hour  ABPM, 
subjects  were  classified  into  four  groups
4, 5). 
(1)  Normotension  (NT)
Clinic  BP  <  140/90  mmHg  and  daytime  BP  <  135/85  mmHg
(2)  Masked  hypertension  (MHT)
Clinic  BP  <  140/90  mmHg  and  daytime  BP  ≥135  mmHg  or  85 
mmHg
(3)  White-coat  hypertension  (WCHT)
Clinic  BP  ≥ 140  or  90  mmHg  and  daytime  BP  <  135/85  mmHg
(4)  Sustained  hypertension  (SHT)
Clinic  BP  ≥ 140  or  90  mmHg  and  daytime  BP  ≥135  mmHg  or 
85  mmHg
Statistical  Methods
Continuous  variables  are  represented  as  mean  standard 
deviation,  and  categorical  variables  as  frequency  and 
percentage.  Pearson's  correlation  coefficient  analysis  was  used 
to  assess  correlations  between  blood  pressure  and  LVMI.  The 
NT  and  MHT  groups,  and  the  SHT  and  WCHT  were  compared 
using  chi-square  tests  for  categorical  variables  and  Student's 
t-test  for  continuous  variables.  Multivariate  logistic  regression 
analysis  was  used  to  determine  whether  any  baseline 
demographic  or  clinical  factors  were  predictive  of  MHT  and 
WCHT.  All  statistical  analyses  were  performed  using  SPSS  12.0 
for  Windows.  A  p-value  <  0.05  was  defined  as  statistically 
significant.
RESULTS
Baseline  characteristics
The  mean  age  of  the  967  subjects  was  51.9±11.9  years.  Of 
these  individuals,  52%  were  male,  32%  were  current  smokers, 
and  41.9%  were  habitual  drinkers.  In  addition,  87.1%  (886)  were 
taking  one  or  more  antihypertensive  medications,  and  13.7% 
had  a  family  history  of  hypertension.  Overall,  the  mean  clinic  BP 
was  157.7±22.0/95.3±13.1  mmHg,  and  the  mean  daytime 
ambulatory  BP  was  136.4±15.0/  86.2±10.7  mmHg.  The  NT, 
MHT,  WCHT,  and  SHT  groups  consisted  of  51  (5.3%),  55 
(5.7%),  273  (28.2%),  and  588  (60.8%)  subjects,  respectively 
(Table  1). 
Compared  with  the  NT  group,  the  MHT  group  had  a  lower 
mean  age,  higher  mean  body  mass  index,  and  higher 
percentages  of  males  and  habitual  drinkers  (p<0.05  each).  In 
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Variables All  subjects
Clinic  BP<140/90  mmHg
p*
Clinic  BP≥140/90  mmHg
p
†
NT MHT WCHT SHT
n  (%)
Age  (year)
Sex  (%  woman)
BMI  (kg/m
2)
Current  smoker  (%)
Habitual  drinker  (%)
FHx  of  HT  (%)
Clinic  BP
Systolic
Diastolic
Daytime  BP
Systolic
Diastolic
967  (100)
51.9±11.9
48.2
25.2±3.1
32.7
41.9
13.7
157.7±22.0
95.3±13.1
136.4±15.0
86.2±10.7
51  (5.3)
56.2±10.0
60.8
24.3±3.0
25.5
23.5
7.8
124.7±10.1
77.7±8.2
119.0±8.2
74.8±6.2
55  (5.7)
51.2±10.1
93.2
25.8±3.3
36.4
47.3
5.5
128.5±8.2
82.0±5.5
138.9±9.0
90.4±5.3
0.013
0.007
0.021
0.227
0.011
0.709
0.038
0.002
<0.0001
<0.0001
273  (28.2)
52.3±12.9
62.3
24.8±3.3
21.2
32.6
13.6
158.3±18.7
93.1±11.8
122.1±7.3
76.±5.7
588  (60.8)
51.4±11.7
41.8
25.4±2.9
38.3
47.3
15.0
163.1±20.1
99.1±12.1
144.4±12.0
91.3±9.1
0.318
<0.0001
0.005
<0.0001
<0.0001
0.584
0.001
<0.001
<0.0001
<0.0001
*difference  between  NT  and  MHT
†difference  between  WCHT  and  SHT
Table  1.  Baseline  characteristics  of  the  study  subjects
Figure 1. The association between average daytime ambulatory BP/clinic BP and left ventricular mass at echocardiography in all subjects.
a  lower  mean  body  mass  index,  and  lower  percentages  of 
current  smokers  and  habitual  drinkers  than  the  SHT  group 
(p<0.05  each). 
Echocardiographic  Findings
The  SHT  group  had  a  significantly  higher  LVMI  than  the 
WCHT  group  (p<0.05),  but  LVMI  was  not  significantly  different  in 
the  NT  and  MHT  groups.  LVMI  showed  significant  positive 
correlations  with  both  cli0nic  BP  (r=0.305,  p<0.001)  and  mean 
daytime  ambulatory  BP  (r=0.175,  p<0.001)  (Figure  1).  There 
were  no  significant  differences  in  the  percentage  of  patients  with 
increased  AoSA. 
'Masked  Effect'  and  'White  Coat  Effect'
There  were  significant  negative  correlations  between  clinic  BP 
and  mean  daytime  ambulatory  BP  minus  clinic  BP  (awake 
ABPM-clinic  BP)  for  both  systolic  (r=-0.8,  p<0.001)  and  diastolic 
(r=-0.6,  p<0.001)  blood  pressure.  The  white-coat  effect  was 
clear  among  the  subjects  who  exhibited  high  clinic  BP,  while  the 
masked  effect  was  clear  among  subjects  who  exhibited  low 
clinic  BP. 
Predictive  Factors
We  used  univariate  logistic  regression  analysis  to  identify 
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Figure 2. The ambulatory and clinic BP difference in relation to the clinic BP for all subjects. The White-coat hypertension was dominated 
in  subjects  with  high  clinic  BP,  whereas  the  masked  hypertension  was  prevalent  in  those  with  lower  clinic  BP.
Variables All  subjects
Clinic  BP<140/90  mmHg
p*
Clinic  BP≥140/90  mmHg
p
†
NT MHT WCHT SHT
n  (%)
mass  index  (g/m
2)
Increased  Aorto-septal  angle  (%)
Total  cholesterol  (mg/dL)
HDL  cholesterol  (mg/dL)
Uric  acid  (mg/dL)
967  (100)
113.4±28.6
22.6
192.9±36.0
53.0±21.9
5.5±1.4
51  (5.3)
108.1±25.7
27.5
186.9±34.9
54.2±13.1
5.1±1.4
55  (5.7)
107.7±27.9
25.5
192.3±31.6
51.1±11.8
5.6±1.1
0.931
0.816
0.417
0.215
0.042
273  (28.2)
106.8±26.1
23.8
190.4±35.9
54.8±34.3
5.2±1.3
588  (60.8)
117.4±29.4
21.4
194.6±36.4
52.3±14.9
5.6±1.4
<0.0001
0.434
0.119
0.264
<0.0001
*difference  between  NT  and  MHT
†difference  between  WCHT  and  SHT
Table  2.  Echocardiographic  and  laboratory  measurements  of  the  study  subjects
Variable
Univariate  Analysis Multivariate  Analysis
OR 95%  CI p OR 95%  CI p
Age
Sex  (female  vs.  male)
BMI
Clinic  SBP≥130  mmHg
Habitual  drinking
(non-drink  vs.  drink)
0.951
0.314
1.168
2.323
0.343
0.913～0.991
0.154～0.751
1.019～1.339
1.061～5.041
0.149～0.792
0.016
0.008
0.026
0.035
0.12
0.959
0.333
1.204
3.198
0.479
0.915～1.006
0.128～0.866
1.034～1.401
1.150～8.892
0.174～1.317
0.086
0.024
0.017
0.026
0.154
Table  3.  Predictors  of  Masked  Hypertension
MHT  included  younger  age,  male  gender,  higher  body  mass 
index,  clinic  BP  ≥130  mmHg  that  did  not  meet  hypertension 
criteria,  and  habitual  drinking  (Table  3).  Factors  predictive  of 
WCHT  included  female  gender,  lower  body  mass  index,  and 
clinic  BP  that  met  the  hypertension  criteria  but  <150  mmHg 
(Table  4).  Multivariate  logistic  regression  analysis  showed  that 
factors  significantly  predictive  of  MHT  were  male  gender,  higher 
body  mass  index,  and  clinic  BP  ≥130  mmHg,  and  that  factors 
significantly  predictive  of  WCHT  were  female  gender,  lower  body 
mass  index,  and  clinic  BP  <150  mmHg. The  Korean  Journal  of  Internal  Medicine  :  Vol.  22,  No.  4,  December  2007 260
Variable
Univariate  Analysis Multivariate  Analysis
OR 95%  CI p OR 95%  CI p
Sex  (female  vs.  male)
BMI
Clinic  SBP≥150  mmHg
2.295
0.929
0.700
1.709～3.080
0.882～0.978
0.515～0.953
<0.001
0.005
0.024
2.092
0.940
0.660
1.529～2.864
0.892～0.990
0.473～0.921
<0.001
0.019
0.015
Table  4.  Predictors  of  White-coat  Hypertension
DISCUSSION
Large-scale  studies  in  western  countries  on  WCHT  and  MHT 
have  led  to  JNC-7  and  ESC-ESH  guidelines  recommending  the 
use  of  ABPM  for  24  hours
24-26).  However,  ABPM  is  not  widely 
used  in  Korea,  and  their  prevalence  is  not  known.  Here,  we 
assessed  24-hour  ABPM  in  almost  1000  Korean  subjects  to 
determine  the  prevalence  of  both  WCHT  and  MHT. 
Cardiovascular  risk  is  considerably  reduced  if  mean  daytime 
blood  pressure,  determined  by  ABPM,  is  lower  than  135/85 
mmHg,  establishing  this  as  the  normal  upper  limit  of  ABPM
10,
26-29).  However,  many  previous  studies  defined  it  as  under 
125/80  mmHg,  leading  to  differences  in  estimates  of  WCHT 
prevalence:  from  around  10%  in  the  general  population  and 
15%  to  50%  among  those  with  slightly  elevated  blood  pressure. 
Its  prevalence  among  Koreans  with  early  stage  hypertension 
was  28.2%,  perhaps  due  to  the  fact  that  they  were  mildly 
hypertensive  patients. 
MHT,  previously  called  ‘white-coat  normotension’  or  ‘reversed 
WCHT’,  was  first  described  as  a  phenomenon  of  normal  clinic 
BP  and  high  daytime  ambulatory  BP
4, 30).  Its  prevalence  ranges 
from  9%  to  13.4%  in  the  general  population
8, 19)  and  from  7%  to 
22.9%  in  hypertensive  patients
2, 7).  The  prevalence  of  MHT 
observed  in  this  study  was  somewhat  lower,  5.7%,  probably 
because  fewer  young  patients  were  included  in  the  study,  and 
therefore  may  not  reflect  primary  medical  practice.  Furthermore, 
since  this  was  not  a  random  prospective  study,  we  cannot 
exclude  the  possibility  that  MHT  patients  with  normal  clinic  BP 
were  no  longer  followed-up. 
LVMI  correlates  significantly  with  24-hour  daytime  ambulatory 
BP  in  hypertensive  subjects
31),  and  24-hour  daytime  ambulatory 
BP  better  reflects  cardiovascular  risk  than  clinic  BP
2, 3).  We  also 
found  significant  correlations  between  24-hour  daytime  ambula-
tory  BP  and  echocardiographically-determined  LV  hypertrophy 
and  LVMI.  In  contrast  to  previous  studies
13, 15, 19),  however,  we 
did  not  detect  clear  differences  among  the  four  blood  pressure 
groups.  This  may  have  been  due  to  the  relatively  low  number 
of  patients  in  each  group,  although  we  cannot  exclude  the 
possibility  that  LV  hypertrophy  in  some  patients  was  affected  by 
their  past  medication  history.  It  should  be  noted,  however,  that 
all  of  our  subjects  were  recently  diagnosed.  Prospective  studies 
in  large  numbers  of  subjects  are  needed  to  determine  causal 
relationships  between  BP  and  LV  hypertrophy,  as  well  as  to 
determine  if  target  organ  damage  affects  long-term  prognosis. 
While  the  percentage  of  patients  with  AoSA  increases 
significantly  with  age,  there  were  no  significant  differences 
among  the  four  blood  pressure  groups,  perhaps  because  we 
did  not  measure  the  exact  angle. 
We  also  assessed  factors  that  could  distinguish  between  NT 
and  MHT  or  between  WCHT  and  SHT,  which  cannot  be 
differentiated  by  clinic  BP.  In  agreement  with  previous  studies
6,
7, 9, 10, 20),  we  found  that  factors  significantly  predictive  of  MHT 
were  younger  age,  male  gender,  higher  body  mass  index,  and 
clinic  BP  ≥130  mmHg,  while  the  factors  significantly  predictive 
of  WCHT  were  female  gender,  lower  body  mass  index,  and 
hypertensive  clinic  BP  <150  mmHg.  Nicotine-induced  hyper-
function  of  the  sympathetic  nerve  caused  by  smoking  contracts 
the  peripheral  vascular  system  and  raises  BP  for  about  30 
minutes
32, 33).  Since  continual  smoking  raises  daytime  ambulatory 
BP  and  since  subjects  may  temporarily  stop  smoking  before 
visiting  the  clinic,  measured  clinic  BP  may  be  lower  than 
daytime  ambulatory  BP.  Thus,  a  previous  study  reported  that 
smoking  is  predictive  of  MHT,  whereas  not  smoking  is  predictive 
of  WCHT
9).  Although  we  found  that  smoking  status  was  not 
predictive  of  WCHT  or  MHT,  smoking  may  distinguish  among 
hypertensive  groups  because  the  percentage  of  smokers  in  the 
WCHT  group  was  significantly  lower  than  that  in  the  SHT  group. 
Whereas  some  studies  measured  clinic  BP  two  to  three 
times  per  subject  and  averaged  these  values
7, 8),  we  measured 
clinic  BP  only  once.  Our  procedure  may  have  introduced  an 
error  in  the  diagnosis  of  WCHT  by  failing  to  reduce  the  white 
coat  effect.  Furthermore,  the  ABPM  effect,  in  which  average 
blood  pressure  increased  7/4  mmHg  for  the  first  four  hours  after 
wearing  an  ABPM  device
34),  could  cause  errors  in  diagnosis. 
Therefore,  randomized,  prospective  studies,  in  which  clinic  BP  is 
determined  by  measuring  BP  twice  for  each  of  three  visits
35), 
and  in  which  daytime  ambulatory  BP  is  determined  by 
performing  ABPM  for  48  hours  and  taking  the  results  for  the 
second  day,  may  more  accurately  determine  the  correlations 
among  prevalence  rates  of  MHT  and  WCHT,  target  organ 
damage,  and  cardiovascular  risk. 
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and  MHT  among  Korean  hypertensive  patients  were  similar  to 
those  in  western  countries.  ABPM  is  essential  for  diagnosing 
such  patients,  and  better  reflects  target  organ  damage  such  as 
LV  hypertrophy.  These  findings  indicate  that  ABPM  should  be 
used  to  determine  factors  predictive  of  WCHT  and  MHT,  thus 
enabling  early  detection  of  high  risk  patients  and  providing  them 
with  proper  treatment. 
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